Melanocortin Research

MT-2 Refill 10mg

£23.00

MT-2 Refill 10mg · 10mg nominal

the MT-2 cyclic melanocortin analogue in refill format. The separately listed refill-cartridge research product. For in-vitro laboratory research only; not for human or veterinary use.

Request batch documentation

Description

MT-2 Refill 10mg is the Core Research catalogue item for 10mg nominal of the MT-2 cyclic melanocortin analogue in refill format. It is supplied as the separately listed refill-cartridge research product for in-vitro laboratory research only; not for human or veterinary use. The material and model-level science below must be distinguished from product-specific analytical results and finished-format performance.

What you receive and what needs verifying

Field What this product listing establishes
Exact catalogue item MT-2 Refill 10mg
Labelled amount 10mg nominal; not an independently measured quantitative assay
Presentation the separately listed refill-cartridge research product
Research identity the MT-2 cyclic melanocortin analogue in refill format
Supply boundary In-vitro laboratory research only; no personal or veterinary use
Current price and stock Shown by the live WooCommerce purchase panel; not fixed in this description

This is the refill-cartridge product, not the separately sold complete pen. Cartridge capacity, contents/vehicle, compatible hardware, sealed integrity, filled volume, accessories and dispensing tolerance should be established through documentation for this exact finished presentation. Do not transfer those details from a vial.

Before ordering, check the material identity, the form on the actual label and any information your assay needs from the applicable certificate. An unrelated paper, a general PubChem record or another catalogue format cannot establish a batch value for this particular item.

Which compound or format is the right laboratory item?

Different from MT-1 and PT-141. MT-2 is a cyclic melanocortin ligand with a different research profile from longer MT-1 analogues and PT-141. Neither one substitutes for another solely because their experiments address melanocortin receptors.

Format or material Catalogue listing Evidence boundary
10mg MT-2 vial Melanotan II (MT-2) 10mg Separate catalogue record; verify its amount, components and lot evidence
10mg MT-2 refill MT-2 Refill 10mg This item
10mg MT-2 pen mt-2-10mg-pen Separate catalogue record; verify its amount, components and lot evidence
MT-1 vial — different analogue Melanotan I (MT-1) 10mg Separate catalogue record; verify its amount, components and lot evidence

The distinction is not cosmetic: a refill cartridge and an assembled pen answer different procurement questions. See vials versus pen formats and cartridge capacity and precision guide for the kinds of format data researchers should verify. A catalogue label is not a demonstrated compatibility or performance test.

A medicinal formulation or clinical study of a related melanocortin analogue does not validate the laboratory catalogue item. The relevant comparison is identity, sequence/cyclisation, receptor assay, exact format and applicable lot report—not a consumer outcome expectation.

Scientific research: mechanisms, measured results and limits

The following is a selected, model-specific evidence summary, not a systematic review, treatment recommendation or release test of this product. Read the study species, methods and measured endpoints beside each finding before transferring an interpretation to a different assay.

The cyclic MT-II scaffold and its receptor profile

Melanotan II is described in the literature as a lactam-cyclised heptapeptide related to an alpha-MSH recognition sequence. The cyclic scaffold includes a conserved His–D-Phe–Arg–Trp region important for interacting with melanocortin receptors. Unlike the longer MT-1 analogue, MT-II has been used as a relatively broad agonist across several melanocortin receptor subtypes in cell assays. Exact sequence, salt and cyclisation chemistry of the supplied catalogue material must still be established from the specific material record. 1,2

Receptor binding and cAMP are not interchangeable outputs

Bednarek and colleagues synthesised cyclic alpha-MSH analogues derived from MT-II and assessed affinity, potency and cAMP activation across human melanocortin receptor subtypes. Changing a single residue could alter subtype selectivity dramatically. The report also identifies MT-II as active at hMC1, hMC3, hMC4 and hMC5 receptors in the study context. This is molecular pharmacology, not evidence that every cyclic derivative has the same physiological outcomes; the exact ligand and cell system are the essential qualifiers. 1

Pigmentation is only one of several investigated endpoints

A small 1996 controlled pilot examined MT-II observations in three male volunteers. The investigators recorded pigmentation measurements and other physiological and adverse-event observations; nausea, fatigue or somnolence were among the reported events. A study of three people cannot establish long-term safety, efficacy across populations, or an administration protocol for research material. The report is also distinct from evidence for MT-1, PT-141 or a finished refill/pen presentation. 2

Why the clinical observation is not a product specification

The 1996 pilot used a particular investigational preparation and limited study conditions, and it did not measure the purity, stability or finished-format suitability of Core Research products. Even if a biological outcome appeared in the pilot, that does not establish any result for a nominal 10mg research vial or refill. The page keeps receptor-level data, small human observations and supplier-lot evidence in separate categories to prevent a mechanism claim becoming a personal-use recommendation. 2

MT-1, MT-2 and PT-141 need separate experimental owners

MT-1 is generally associated with a longer linear alpha-MSH analogue, MT-II with a constrained cyclic scaffold, and PT-141/bremelanotide with another defined melanocortin-active drug entity. Shared receptor families are not chemical identity. They can differ in sequence, receptor binding, metabolic handling and reported study outcomes. A useful comparison is the intended receptor and model, not an assumption that their commercial names or visual packaging make them interchangeable. 1

How to interpret the evidence for this product

Research context Reported or relevant endpoint Interpretation limit
Human melanocortin receptor-cell assays Ligand affinity and cAMP responses Receptor effects vary by sequence and subtype
Three-volunteer phase-I pilot Pigment changes and observed adverse events Very small and short; no general safety conclusion
Supplied 10mg material or refill Lot identity and finished-format specification Requires supplier evidence; not established by publications

Batch documentation before purchase

Core Research allows a pre-purchase batch-documentation enquiry. Use Batch Documentation or email info@core-research.net with the exact product name and presentation. An order or container lot number is not needed to ask the question before purchase; to match a supplied item after delivery, retain its lot identifier and order reference. The published delivery policy says a certificate is issued with a consignment where one exists for the supplied lot; that is not a promise of a current certificate for every item.

Ask whether documentation applies to the lot proposed for supply and identifies the tested chemical form, sample description, method, result, reporting basis, testing issuer and relevant dates. The difference between chromatographic peak-area purity, identity/mass and quantitative vial content matters.

For interpretation, use guide to reading a CoA, HPLC testing guide and mass-spectrometry guide. A theoretical molecular formula is not a batch-assay result, and a product label does not certify sterility.

For this melanocortin research product, ask the supplier to match the sequence, stereochemistry, terminal groups, cyclic-versus-linear scaffold and counter-ion to the actual lot. The shorthand MT-1 or MT-2 alone cannot verify these fields.

Cartridge and finished-format verification

A compound-level HPLC/LC-MS report supports only the analyte/sample tested. It does not establish cartridge integrity, exact volume, device compatibility, dispensing accuracy or prepared-material stability. If any of these are essential to the intended experimental protocol, request documented values applicable to this exact refill and lot before ordering. pen verification guide covers the main verification questions.

Confirm in writing whether the product is supplied as a complete pen or a refill-only cartridge, and the included component list where not already clear from the listing. Do not infer an accessory or a specific solvent from an image or a sibling product.

Storage, receiving and laboratory quality control

A refill is not necessarily analytically or physically identical to a dry vial. Confirm whether the actual cartridge is filled with liquid or dry material before applying a liquid-stability or storage claim.

Follow the supplied label and product-specific documentation for storage conditions, temperature excursions and expiry. The time limits for dry peptide, a mixed solution, or a liquid-filled cartridge can differ. No generic fixed storage term, purity threshold or cold-chain guarantee is inserted here without applicable evidence. See peptide storage guidance and research-product receiving checklist for general laboratory-record practices.

At receipt, compare the product name, labelled amount and presentation with your order. Inspect the vial closure or cartridge/packaging, record the lot identifier and retain the accompanying paperwork. If damaged, delayed or different from the order, record photographs and contact Core Research before using the material. This records receipt conditions; it does not substitute for an identity assay.

Ordering questions

Does the labelled milligram amount state purity or a prepared concentration?

No. 10mg is the catalogue-labelled quantity for this item. It does not by itself establish analytical content, purity, final liquid concentration, sample mass basis or number of experiments. The applicable material documentation and your laboratory’s own method establish those details.

Where is the product dispatched from and what is the delivery policy?

Core Research states that it dispatches from Birmingham, United Kingdom, using plain external packaging. Delivery service, charge and arrival estimates depend on the destination and order; see Shipping & Delivery. Tracking is provided in dispatch communications where available. There is no universal next-day delivery or free-shipping promise on this page.

Can I obtain an applicable certificate before ordering?

You can request information before ordering through Batch Documentation. Specify MT-2 Refill 10mg, the refill presentation and any required test/method. Whether a particular current lot has a document, and what it actually reports, must be checked rather than assumed.

Can an institution request a quotation?

Yes. Institutional Procurement describes the written quotation and purchase-order-reference enquiry route. Include the institution, delivery details, exact product and quantity, and any lot or technical requirements. An enquiry does not itself reserve stock or guarantee credit terms.

Is this product suitable for human or veterinary use?

No. This listing is for in-vitro laboratory research only. Neither a positive model result nor a named medicinal compound establishes human-use suitability, and this page gives no preparation, dosing or administration instructions. See Research Use Only policy.

Order or enquire about MT-2 Refill 10mg

Use the native product purchase panel to select the listed quantity and the checkout options available for your order. For identity, format, lot-documentation or delivery questions, contact Core Research before purchase. Current price and stock remain controlled by WooCommerce, not hard-coded in this description.

Selected research references

[1] Bednarek MA et al. (2008). Cyclic alpha-MSH analogues and human melanocortin receptor subtype-binding and cAMP assays. Peptides. PMID 18378043. DOI 10.1016/j.peptides.2008.02.008. Primary research record.

[2] Dorr RT et al. (1996). Pilot phase-I research on Melanotan-II, a cyclic melanotropic peptide, with three adult volunteers. Life Sciences. PMID 8637402. DOI 10.1016/0024-3205(96)00160-9. Primary research record.

Additional information

Format

Refill cartridge

Strength

10mg